Blunted psychotomimetic and amnestic effects of Δ-9- tetrahydrocannabinol in frequent users of cannabis

Neuropsychopharmacology

Volumn 33, Issue 10, 2008, Pages 2505-2516

  D'Souza, Deepak Cyril ^a,b,c   Ranganathan, Mohini ^a,c   Braley, Gabriel ^a,c   Gueorguieva, Ralitza ^b,d   Zimolo, Zoran ^a,c   Cooper, Thomas ^e,f   Perry, Edward ^a,c   Krystal, John ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

^e Columbia University ^*  (United States)

^f NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Abuse; Cannabinoids; Cannabis; Cognition; Delta 9 tetrahydrocannabinol; Memory; Tolerance

Indexed keywords

CANNABIS; DRONABINOL; PLACEBO;

ADULT; ANXIETY; ARTICLE; ATTENTION; CANNABIS ADDICTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFECT; DRUG EXPOSURE; DRUG TOLERANCE; EUPHORIA; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MEMORY DISORDER; PERCEPTION DISORDER; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA;

ADOLESCENT; ADULT; AMNESIA; ATTENTION; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HALLUCINATIONS; HALLUCINOGENS; HUMANS; HYDROCORTISONE; MALE; MARIJUANA ABUSE; MIDDLE AGED; PERCEPTUAL DISORDERS; PROLACTIN; PSYCHOSES, SUBSTANCE-INDUCED; TACHYCARDIA; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 44549087417     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301643     Document Type: Article

References (92)

1. Abood ME, Sauss C, Fan F, Tilton CL, Martin BR (1993). Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 46: 575-579.
2. Anthony JC, Trinkoff AM (1989). United States epidemiologic data on drug use and abuse: how are they relevant to testing abuse liability of drugs? NIDA Res Monogr 92: 241-266.
3. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ (1995). Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23: 825-831.
4. Brandt J (1991). 'The hopkins verbal learning test. Development of a new memory test with 6 equivalent forms'. Clin Neuropsychol 5: 125-142.
5. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 2447-2459.
6. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125-136.
7. Brunner E, Domhof S, Langer F (2002). Nonparametric Analysis of Longitudinal Data in Factorial Experiments. John Wiley and Sons: New York, NY.
8. Budney AJ, Hughes JR, Moore BA, Vandrey R (2004). Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161: 1967-1977.
9. Bylsma FW, Rebok GW, Brandt J (1991). Long-term retention of implicit learning in Huntington's disease. Neuropsychologia 29: 1213-1221.
10. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57: 1117-1127.
11. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004). Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 291: 2114-2121.
12. Conrod PJ, Peterson JB, Pihl RO (2001). Reliability and validity of alcohol-induced heart rate increase as a measure of sensitivity to the stimulant properties of alcohol. Psychopharmacology (Berl) 157: 20-30.
13. de Miguel R, Romero J, Munoz RM, Garcia-Gil L, Gonzalez S, Villanua MA et al (1998a). Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. Biochem Pharmacol 56: 1331-1338.
14. de Miguel R, Romero J, Munoz RM, Garcia-Gil L, Gonzalez S, Villanua MA et al (1998b). Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. Biochem Pharmacol 56: 1331-1338.
15. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J et al (2000). Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 74: 1627-1635.
16. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9- tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
17. D'Souza DC (2007). Cannabinoids and psychosis. Int Rev Neurobiol 78: 289-326.
18. Eissenberg T, Balster RL (2000). Initial tobacco use episodes in children and adolescents: current knowledge, future directions. Drug Alcohol Depend 59(Suppl 1): S41-S60.
19. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003b). Cannabis dependence and psychotic symptoms in young people. Psychol Med 33: 15-21.
20. Fergusson DM, Horwood LJ, Lynskey MT, Madden PA (2003a). Early reactions to cannabis predict later dependence. Arch Gen Psychiatry 60: 1033-1039.
21. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders Non-patient edition. In: American Psychiatric Association, Washington, DC.
22. Gonzalez S, Manzanares J, Berrendero F, Wenger T, Corchero J, Bisogno T et al (1999). Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology 70: 137-145.
23. Gonzalez S, Cebeira M, Fernandez-Ruiz J (2005). Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 81: 300-318.
24. Gordon M (1986). Microprocessor-based assessment of attention deficit disorders (ADD). Psychopharmacol Bull 22: 288-290.
25. Green B, Kavanagh D, Young R (2003). Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 22: 453-460.
26. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A (1994). Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25: 161-164.
27. Haertzen CA (1965). Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis 141: 300-307.
28. Haertzen CA (1966). Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep 18: 163-194.
29. Hall W, Degenhardt L, Teesson M (2004). Cannabis use and psychotic disorders: an update. Drug Alcohol Rev 23: 433-443.
30. Hampson RE, Simeral JD, Kelly EJ, Deadwyler SA (2003). Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. Hippocampus 13: 543-556.
31. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a). Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141: 385-394.
32. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 141: 395-404.
33. Harclerode J (1984). Endocrine effects of marijuana in the male: preclinical studies. In: Braude MC and Ludford JP (eds). NIDA Research Monograph Series. National Institute on Drug Abuse: Rockville, MD, pp 45-114.
34. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M et al (2006a). An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31: 2748-2757.
35. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M et al (2006b). An experimental study of catechol-O-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol- induced effects on psychosis and cognition. Neuropsychopharmacology 31: 2748-2757.
36. Henquet C, Murray R, Linszen D, van Os J (2005). The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31: 608-612.
37. Hollister LE (1988). Cannabis-1988. Acta Psychiatr Scand Suppl 345: 108-118.
38. Hopfer CJ, Lessem JM, Hartman CA, Stallings MC, Cherny SS, Corley RP et al (2007). A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: evidence for linkage on chromosomes 3 and 9. Drug Alcohol Depend 89: 34-41.
39. Hopfer CJ, Young SE, Purcell S, Crowley TJ, Stallings MC, Corley RP et al (2006). Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am J Med Genet B Neuropsychiatr Genet 141: 895-901.
40. Jones RT, Benowitz N, Bachman J (1976). Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 282: 221-239.
41. Jones RT, Benowitz NL, Herning RI (1981). Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21: 143S-152S.
42. Kandel DB, Chen K (2000). Types of marijuana users by longitudinal course. J Stud Alcohol 61: 367-378.
43. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry-Suppl 59-67.
44. Kelleher LM, Stough C, Sergejew AA, Rolfe T (2004). The effects of cannabis on information-processing speed. Addict Behav 29: 1213-1219.
45. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L et al (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94: 29-36.
46. Leweke FM, Gerth CW, Klosterkotter J (2004). Cannabis-associated psychosis: current status of research. CNS Drugs 18: 895-910.
47. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 66: 175-181.
48. Leweke FM, Schneider U, Thies M, Munte TF, Emrich HM (1999). Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berl) 142: 230-235.
49. Leweke FM (2007). Cannabidiol as an antipsychotic - new perspectives. In: 2nd International Cannabis and Mental Health Conference. Institute of Psychiatry: London, UK.
50. Lichtman AH, Martin BR (2005). Cannabinoid tolerance and dependence. Handb Exp Pharmacol 168: 691-717. Review.
51. Lichtman AH, Varvel SA, Martin BR (2002). Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66: 269-285.
52. Lyons MJ, Toomey R, Meyer JM, Green AI, Eisen SA, Goldberg J et al (1997). How do genes influence marijuana use? The role of subjective effects. Addiction 92: 409-417.
53. Martin BR, Sim-Selley LJ, Selley DE (2004). Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 25: 325-330.
54. Mechoulam R, Ben-Shabat S (1999). From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 16: 131-143.
55. Murphy LL, Munoz RM, Adrian BA, Villanua MA (1998a). Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 5: 432-446.
56. Murphy LL, Munoz RM, Adrian BA, Villanua MA (1998b). Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 5: 432-446.
57. Newlin DB, Thomson JB (1990). Alcohol challenge with sons of alcoholics: a critical review and analysis. Psychol Bull 108: 383-402.
58. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100.
59. Pertwee RG, Stevenson LA, Griffin G (1993). Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. [erratum appears in Br J Pharmacol 1994 Mar; 111(3):968]. Br J Pharmacol 110: 1483-1490.
60. Pollock VE (1992). Meta-analysis of subjective sensitivity to alcohol in sons of alcoholics. Am J Psychiatry 149: 1534-1538.
61. Rodriguez De Fonseca F, Fernandez-Ruiz JJ, Murphy LL, Cebeira M, Steger RW, Bartke A et al (1992). Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol, Biochem Behav 42: 269-275.
62. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA (1994). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47: 33-40.
63. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA et al (1998). Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298-308.
64. Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA (1995). Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. Pharmacol Biochem Behav 51: 731-737.
65. Rubino T, Vigano D, Massi P, Parolaro D (2000a). Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 75: 2080-2086.
66. Rubino T, Vigano D, Massi P, Spinello M, Zagato E, Giagnoni G et al (2000b). Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39: 1331-1336.
67. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D (1997). Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 44: 191-197.
68. Russo EB, McPartland JM (2003). Cannabis is more than simply delta(9)-tetrahydrocannabinol. [comment]. Psychopharmacology 165: 431-432; author reply 433-434.
69. SAMHSA (2004). Results from the 2003 national survey on drug use and health: national findings. Substance Abuse and Mental Health Services Administration: Rockville, MD.
70. Schuckit MA, Greenblatt D, Gold E, Irwin M (1991b). Reactions to ethanol and diazepam in healthy young men. J Stud Alcohol 52: 180-187.
71. Schuckit MA, Tsuang JW, Anthenelli RM, Tipp JE, Nurnberger Jr JI (1996). Alcohol challenges in young men from alcoholic pedigrees and control families: a report from the COGA project. J Stud Alcohol 57: 368-377.
72. Schuckit MA, Duthie LA, Mahler HI, Irwin M, Monteiro MG (1991a). Subjective feelings and changes in body sway following diazepam in sons of alcoholics and control subjects. J Stud Alcohol 52: 601-608.
73. Schuckit MA, Smith TL, Anderson KG, Brown SA (2004). Testing the level of response to alcohol: social information processing model of alcoholism risk-a 20-year prospective study. Alcohol Clin Exp Res 28: 1881-1889.
74. Schuckit MA (1985a). Behavioral effects of alcohol in sons of alcoholics. Recent Dev Alcohol 3: 11-19.
75. Schuckit MA (1985c). Ethanol-induced changes in body sway in men at high alcoholism risk. Arch Gen Psychiatry 42: 375-379.
76. Schuckit MA (2000). Genetics of the risk for alcoholism. Am J Addict 9: 103-112.
77. Schuckit MA (1994). Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatry 151: 184-189.
78. Schuckit MA (1985b). The clinical implications of primary diagnostic groups among alcoholics. Arch Gen Psychiatry 42: 1043-1049.
79. Sim-Selley LJ, Martin BR (2002). Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1, 4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303: 36-44.
80. Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR. et al (2006). Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 70: 986-996.
81. Slosson RL (1963). Slosson Intelligence Test (SIT) for Children and Adults. In: Slosson Educational Publications: East Aurora, NY.
82. Sobell LC, Sobell MB (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. Litten AR, Totowa J (eds). Measuring Alcohol Consumption. The Humana Press: NJ, USA.
83. Solowij N (1998). Cannabis and Cognitive Functioning. Cambridge University Press: Cambridge.
84. Solowij N (1995). Do cognitive impairments recover following cessation of cannabis use? Life Sci 56: 2119-2126.
85. Stinson FS, Ruan WJ, Pickering R, Grant BF (2006). Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 36: 1447-1460.
86. Verdoux H, Tournier M (2004). Cannabis use and risk of psychosis: an etiological link? Epidemiologia e Psichiatria Sociale 13: 113-119.
87. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002). Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 161: 331-339.
88. Weiser M, Noy S (2005). Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7: 81-85.
89. Whitlow CT, Freedland CS, Porrino LJ (2003). Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 71: 169-177.
90. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76: 245-250.
91. Zuardi AW, Rodrigues JA, Cunha JM (1991). Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104: 260-264.
92. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995). Antipsychotic effect of cannabidiol [letter]. J Clin Psychiatry 56: 485-486.